New immune cell therapy tested for tough blood cancers
NCT ID NCT06730256
Summary
This is an early-phase study testing a new type of personalized immune cell therapy called CT0596 CAR-T. It aims to see if this treatment is safe and effective for adults with multiple myeloma or plasma cell leukemia that has come back or stopped responding to other treatments. The study will enroll 24 participants to find the right dose and see how well the modified immune cells fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.